Journal
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume 1397, Issue 1, Pages 5-16Publisher
WILEY
DOI: 10.1111/nyas.13337
Keywords
claudin; monoclonal antibody; hepatitis C virus; cancer; epidermal absorption
Categories
Funding
- Health and Labour Sciences Research grant from the Ministry of Health, Labour, and Welfare of Japan
- Ministry of Education, Culture, Sports, Science, and Technology of Japan [24390042]
- target-driven RAMP
- D, Japan Science and Technology Agency
- platform for drug discovery, informatics, and structural life science of the Ministry of Education, Culture, Sports, Science, and Technology, Japan
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- Japan Society for the Promotion of Science
- Grants-in-Aid for Scientific Research [16H05164, 24390042] Funding Source: KAKEN
Ask authors/readers for more resources
The 27-member family of tetraspan membrane proteins known as claudins (CLDNs) is a major component of tight junctions. A series of studies elucidating the relationship between CLDNs and various pathological conditions has provided new insights into drug development. For instance, CLDN-1 may be a potent target for epidermal absorption of drugs and for treating hepatitis C virus (HCV) infection. CLDN-4 may be a target for treating cancer. Because CLDNs are also expressed in various normal tissues, safety and efficacy evaluations are critical for translational research. We previously developed several anti-CLDN antibodies and have established proof of concept for CLDN-targeted drug development using these reagents. Here, we provide an overview of CLDN-1 as a target for improving epidermal drug absorption and preventing HCV infection and of CLDN-4 as a target for anticancer therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available